BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28992652)

  • 1. Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
    Cohen C; Pop D; Venissac N; Poudenx M; Otto J; Castelnau O; Mouroux J
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):129-134. PubMed ID: 28992652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Takemoto M; Oto T; Takigawa N; Fujiwara T; Miyoshi S; Date H
    Interact Cardiovasc Thorac Surg; 2012 May; 14(5):565-9. PubMed ID: 22354091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Kaya AO; Buyukberber S; Benekli M; Coskun U; Sevinc A; Akmansu M; Yildiz R; Ozturk B; Yaman E; Kalender ME; Orhan O; Yamac D; Uner A;
    Med Oncol; 2010 Mar; 27(1):152-7. PubMed ID: 19242825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
    Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
    Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
    Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
    World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?
    Sato H; Soh J; Hotta K; Katsui K; Kanazawa S; Kiura K; Toyooka S
    Ann Thorac Cardiovasc Surg; 2018 Jun; 24(3):131-138. PubMed ID: 29681596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does dose matter? Effect of two different neoadjuvant protocols in advanced NSCLC.
    Steger V; Veit S; Walker T; Friedel G; Lehrach K; Mustafi M; Walles T
    Thorac Cardiovasc Surg; 2013 Mar; 61(2):109-15. PubMed ID: 22821672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
    Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
    Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.